Search
Delapril
go.drugbank.com/drugs/DB13312InvestigationalCategories: Agents Acting on the Renin-Angiotensin SystemMongersen
go.drugbank.com/drugs/DB15019InvestigationalMongersen is under investigation in clinical trial NCT02957474 (A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects
Cepeginterferon alfa-2B
go.drugbank.com/drugs/DB12814InvestigationalCepeginterferon alfa-2B is under investigation in clinical trial NCT01889433 (An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic
Solenopsis richteri
go.drugbank.com/drugs/DB11026ApprovedSolenopsis richteri allergenic extract is used in allergenic testing. It is extracted from the black imported fire ant which is native to South Amercia. … The species has also been introduced in North Amercia. When stung, the bites are characterized by sterile pustules that are surrounded by reddened swelling along with redness extending beyond.
Cyclomethicone 5
go.drugbank.com/drugs/DB11244ApprovedCyclomethicones are cyclic in structure with a monomer backbone of one silicon and two oxygen atoms bonded together. Cyclomethicone 5 is used in cosmetic and personal products as a skin emollient.
Ulimorelin
go.drugbank.com/drugs/DB12128InvestigationalUlimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility
DLO6002
go.drugbank.com/drugs/DB05179ExperimentalDLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Staurosporine
go.drugbank.com/drugs/DB02010ExperimentalAn indolocarbazole that is a potent protein kinase C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)
Tasquinimod
go.drugbank.com/drugs/DB05861InvestigationalThe quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts